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Plasma coenzyme QͷͶ status 
is impaired in selected genetic 
conditions
Raquel Monteroͷ,͸, Delia Yuberoͷ, Maria C. Salgadoͷ, María Julieta Gonzálezͷ, 
Jaume Campistolͷ,͸, Maria del Mar O’Callaghanͷ,͸, Mercè Pinedaͷ, Verónica Delgadilloͷ, 
Joan Maynou͹, Guerau Fernandez͹, Julio Montoya͸,ͺ, Eduardo Ruiz-Pesini͸,ͺ, Silvia Meavillaͷ, 
Viruna Neergheenͻ, Angels García-Cazorlaͷ,͸, Placido Navas͸,ͼ, Iain Hargreavesͻ,ͽ & 
Rafael Artuch  ͷ,͸
Identifying diseases displaying chronic low plasma Coenzyme QͷͶ (CoQ) values may be important to 
prevent possible cardiovascular dysfunction. The aim of this study was to retrospectively evaluate 
plasma CoQ concentrations in a large cohort of pediatric and young adult patients. We evaluated 
plasma CoQ values in ͻͿͽ individuals (age range ͷ month to ͺ͹ years, average ͷͷ years), studied 
during the period ͸ͶͶͻ–͸Ͷͷͼ. Patients were classiied into ͼ diferent groups: control group of healthy 
participants, phenylketonuric patients (PKU), patients with mucopolysaccharidoses (MPS), patients 
with other inborn errors of metabolism (IEM), patients with neurogenetic diseases, and individuals with 
neurological diseases with no genetic diagnosis. Plasma total CoQ was measured by reverse-phase 
high-performance liquid chromatography with electrochemical detection and ultraviolet detection 
at ͸ͽͻ nm. ANOVA with Bonferroni correction showed that plasma CoQ values were signiicantly 
lower in the PKU and MPS groups than in controls and neurological patients. The IEM group showed 
intermediate values that were not signiicantly diferent from those of the controls. In PKU patients, 
the Chi-Square test showed a signiicant association between having low plasma CoQ values and being 
classic PKU patients. The percentage of neurogenetic and other neurological patients with low CoQ 
values was low (below ;%). In conclusión, plasma CoQ monitoring in selected groups of patients with 
diferent IEM (especially in PKU and MPS patients, but also in IEM under protein-restricted diets) seems 
advisable to prevent the possibility of a chronic blood CoQ suboptimal status in such groups of patients.
Coenzyme Q10 (CoQ) is a lipid that acts in the mitochondrial respiratory chain as an electron transporter essen-
tial for ATP synthesis and serves as a lipophilic antioxidant, among other functions1. he benzoquinone ring of 
CoQ is derived from tyrosine, while the polyprenyl side-chain comes from acetyl-CoA, through the mevalonate 
pathway, which is common to the synthesis of other lipids such as dolichol and cholesterol, in a tightly regulated 
process2. Blood CoQ status depends on liver biosynthesis and is also the result of dietary sources that can inlu-
ence plasma CoQ concentrations, contributing up to 25% of the total amount3. For CoQ, all tissues and cells are 
able to synthesize the suicient amounts necessary for their diferent biological functions; therefore, no noticeable 
degree of uptake of CoQ seems to occur between the blood and tissues4.
In blood, CoQ is transported by the lipoprotein cholesterol (Chol) transporters5. CoQ has been shown to be 
very eicient in preventing low-density lipoprotein (LDL) oxidation6. Since oxidized LDL is considered to have a 
key function in the development of the atherosclerotic process leading to cardiovascular diseases, treatment with 
CoQ to prevent this oxidation may have therapeutic value. Accordingly, clinical trials of CoQ supplementation 
to patients sufering from cardiovascular diseases have reported a reduction in the level of biochemical markers 
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associated with pathology and major adverse cardiovascular events7,8. herefore, identifying diseases displaying 
chronic low plasma CoQ values may be important to prevent possible cardiovascular dysfunction. he relation-
ship between total blood Chol and CoQ is based on the rationale that both of these molecules share a common 
biosynthetic pathway, the mevalonate pathway9. hus, the simultaneous measurement of plasma CoQ and Chol 
levels is of interest to assess the relationship between the presence of these two lipids in the blood10 and may there-
fore predict the potential for the oxidative damage of the cholesterol transporter lipoproteins11.
Some genetic and environmental conditions have been associated with a decreased level of plasma CoQ val-
ues in pediatric patients12–18. hus, plasma CoQ status may be a valuable biomarker for certain diseases, both for 
diagnosis and treatment monitoring. Moreover, the key role of CoQ in the protection of Chol lipoprotein against 
free-radical damage strongly advocates the identiication of patients presenting with chronic low plasma CoQ 
values.
In view of the diagnostic potential of plasma CoQ status, the aim of this study was to retrospectively evaluate 
plasma CoQ concentrations and CoQ/Chol ratios in a cohort of pediatric and young adult patients from a period 
of 12 years. We focused on those patients presenting with low plasma CoQ values, assessing genetic and environ-
mental factors that could inluence plasma CoQ status.
Methods
Subjects. We retrospectively evaluated our database containing 597 individuals (age range 1 month to 43 
years, average 11 years), studied during the period 2005–2016 in Hospital Sant Joan de Déu (Barcelona) and in 
the Great Ormond Street Hospital (London). Patients were classiied into 6 diferent groups: control group of 
healthy participants, phenylketonuric (PKU) patients due to mutations at the PAH gene encoding phenylala-
nine hydroxylase, patients with mucopolysaccharidoses (MPS), patients with other inborn errors of metabolism 
(IEM), patients with neurogenetic diseases, and lastly individuals with neurological diseases with no genetic 
diagnosis. Details of these cohorts of patients are provided in Table 1 and in the Supplementary Material 1. From 
the latter group, we selected 9 cases who were found to have low plasma CoQ values associated with a neuro-
logical syndrome for genetic diagnosis through next-generation sequencing (NGS). Total Chol values were also 
analyzed from the PKU, MPS, and IEM groups (Table 1). he criteria for the group classiication were: i) Patients 
under restricted dietary treatment and at the risk of a suboptimal CoQ status: PKU and IEM patients. ii) Patients 
with MPS, since these patients may present with low CoQ values, but they are not under dietary restriction. iii) 
Patients with neurogenetic conditions just to identify diseases that may present with low plasma CoQ levels. iv) 
Neuropediatric patients with no diagnosis, to assess whether CoQ status would be a surrogate biomarker for the 
diagnosis of genetic related primary or secondary CoQ deiciencies.
Controls were healthy children with no chronic pharmacological treatments submitted to our Hospital for 
minor surgical interventions (mainly phimosis, adenoids and tympanic drainage). he diferent groups of dis-
eases studied here were excluded based on: (1) biochemical data: most of them underwent the expanded newborn 
screening programs that include PKU and other IEM groups. (2) Clinical data: controls were healthy children 
with no neurological complications, while the MPS, neurogenetic and other neuropediatric patients included in 
the present study were severely handicapped.
From the 113 PKU patients, the type of PAH gene mutation was determined in 89 patients, as reported19 
(Supplementary Data Set). he assigned value study classiies the mutations as 4 categories (1 classic PKU, 2 
moderate PKU, 4 Mild PKU, and 8 mild HPA) for every mutant PAH allele. hus, the sum of the scores obtained 
for every allele led to the inal classiication of patients. In 65 out of 113 PKU patients, the predicted residual PAH 
activity was also calculated as previously reported20. Both variables (assigned value and residual PAH activity) 
were studied as predictors of the risk of developing low plasma CoQ values. All PKU patients were under dietary 
treatment at the time of the study, as previously reported21.
For the 44 MPS patients (Table 1), we increased the number of patients studied in our previous work15 from 
Sanilipo to include patients with other MPS disorders (Supplementary Material 1). For the 61 IEM patients, we 
compared CoQ values in a subgroup on a carbohydrate-restricted diet (galactosemic and fructosemia) with those 
of a group on protein-restricted diets (homocystinurias, organic acidurias, urea cycle defects, and other aminoac-
idopathies) (Supplementary Material 1).
Exclusion criteria included patients taking CoQ. Blood samples were taken in the morning ater an 8–12 h 
fasting period. Blood samples were collected into evacuated glass tubes containing heparin. Blood was immedi-
ately centrifuged at 4 °C (1500xg), and the plasma samples were stored at −80 °C until analysis.
Ethical issues. All patient samples were obtained in accordance with the 2013 revised Helsinki Declaration 
of 1964. For biochemical and genetic investigations, informed consent was collected from patients or their guard-
ians. he Ethical Committee of Sant Joan de Déu Hospital approved the study.
Biochemical methods. Serum total Chol values were analyzed by the automated cholesterol oxidase pro-
cedure in an Architect autoanalyzer (Abbot). Plasma total CoQ, the sum of the reduced form ubiquinol plus the 
oxidized ubiquinone, was measured by reverse-phase high-performance liquid chromatography with electro-
chemical detection and with ultraviolet detection at 275 nm, as previously reported22,23. Plasma CoQ determi-
nation was accredited by the norm ISO15189 (ENAC). Reports regarding this accreditation are available upon 
request. In Fig. 1, typical chtomatograms from internal quality control material and human plasma samples are 
depicted. As we can see in the Fig. 1, the separation of CoQ and internal standard is optimal and both electro-
chemical and ultraviolet detection systems are speciic for CoQ analysis in complex matrixes such as plasma, 
HPLC-electrochemical detection having a greater sensitivity when compared with ultraviolet detection or other 
approaches.
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Genetic analysis. A PKU and MPS mutation study was performed by Sanger sequencing and NGS tech-
nology, as previously reported24. For the 9 selected patients with unknown neurological conditions and plasma 
CoQ deiciency, we applied a commercial panel (TruSight One Sequencing Panel, Illumina) and a NextSeq. 500 
sequencer (Illumina) to screen a maximum number of candidate genes.
Statistical methods. he Pearson correlation test was used to determine the correlations among plasma 
CoQ and Chol values and the patient age and to correlate PAH residual activity with plasma CoQ concentra-
tion. he ANOVA with Bonferroni correction test was applied to compare plasma CoQ, Chol, and CoQ/Chol 
values among the diferent cohorts of patients and controls. Student T test was used to compare CoQ status in 
IEM patients with diferent dietary treatment (carbohydrate and protein-restricted). Chi-Square test was used to 
search for an association between the type of mutations (classiied according to 25) and the CoQ status (deicient 
or not) in the PKU cohort. Statistical calculations were performed using SPSS 23.0 sotware.
Results
In the control group, a highly positive correlation was observed between plasma CoQ and total Chol values 
(Pearson test; r = 0.523; p < 0.0001) (Supplementary Figure 1). No correlation was observed between the age and 
plasma CoQ and CoQ/Chol values in controls under 22 years of age. hus, a unique reference interval was estab-
lished for this group (Table 1). We deined low plasma CoQ values as those below the lowest limit of the reference 
interval established in our laboratory, which was 0.38 µmol/L corresponding to the 2.5 percentile (Table 1).
Figure 1. Typical chromatograms (HPLC with electrochemical detection) from: Let panel. Commercial 
control (Coenzyme Q10 Chromsystens, level 1 (Ref. 0092): CoQ10 = 0.56 µmol/L), based on serum matrix. 
Middle panel. Human plasma sample with CoQ10 = 1.18 µmol/L. Right panel. Human plasma sample with 
CoQ10 = 0.38 µmol/L. Samples, calibrators and controls are spiked with internal standard (Coenzyme Q9 
(CoQ9)).
Subject groups: age range 
(average)
Plasma CoQ 
(µmol/L)
Plasma Chol 
(mmol/L)
Plasma CoQ/Chol 
(µmol/mol)
Number of low CoQ 
values cases
PKU (n = 113)
9m-43y (16.8)
0.20–1–18 (0.49)
SD = 0.20
2.46–8.36 (3.74)
SD = 0–74
51–324 (132)
SD = 49.7
CoQ: 37/113
CoQ/Chol: 33/113
MPS (n = 44)
3–25 y (11.4)
0.16–0.93 (0.40)
SD = 0.17
3.14–6.35 (4.40)
SD = 0.85
29–201 (94)
SD = 40.3
CoQ 24/44
CoQ/Chol 17/30
IEM (n = 61)
6m-40y (10.4)
0.18–1.21 (0.55)
SD = 0.19
2.27–5.89 (4.04)
SD = 0.85
69–291 (139)
SD = 46.2
CoQ 11/61
CoQ/Chol 13/61
Neurogenetic conditions (n = 99)
1m-27y (10.3)
0.25–1–30 (0.67)
SD = 0.21
n.a n.a CoQ 5/99
Other neurological disorders 
(n = 197)
1m-35y (8.2)
0.20–1.67 (0.68)
SD = 0.27
n.a n.a CoQ 19/197
Control group (n = 83)
8m-22y (10.6)
0.38–1.34 (0.65)
SD = 0.24
2.46–5.88 (4.01)
SD = 0.77
101–283 (163)
SD = 51
Table 1. Plasma CoQ and Chol concentrations in controls and 5 groups of patients. Reference values are 
stated as range (deined as 2.5 and 97.5 percentiles), average (in brackets) and SD. For patient groups, data are 
represented as range (average and standard deviation). Age is expressed as range (average). Only the PKU group 
showed a signiicantly higher average age when compared with the other groups. In PKU cases elder than 22 
years of age, the % of low plasma CoQ values was slightly higher when compared with to those younger than 22 
years of age (8 out of 22). *m: months of age. y: years of age.
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Plasma CoQ, Chol, CoQ/Chol ratio values, and the number of cases with low plasma CoQ values in the difer-
ent cohorts of patients are stated in Table 1 and Fig. 2. ANOVA with Bonferroni correction showed that plasma 
CoQ values were signiicantly lower in the PKU and MPS groups than in controls and neurological patients. IEM 
group showed intermediate values that were not signiicantly diferent from those of the controls (Fig. 2, Tables 1 
and 2). When we compared the CoQ/Chol ratios in these 3 groups, MPS values were signiicantly lower than 
controls, PKU, and IEM (Tables 1 and 2). In turn, IEM and PKU patients showed signiicantly lower values than 
controls (Table 2). he highest percentage of patients with low-plasma CoQ and Q/Chol values belonged to the 
MPS group. In this group, low plasma CoQ value was a consistent feature in Sanilippo patients, but it was also 
present in other MPS patients, except for Hurler-Scheie and Maroteaux-Lamy patients (data not shown). Even 
MPS patients with normal CoQ values displayed plasma CoQ concentrations close to the lowest limit of our 
reference interval.
In 65 PKU cases, we studied the correlation between CoQ concentration, the residual predicted PAH activity, 
and the Phe value at diagnosis (as a predictor of disease severity). As expected, residual PAH activity was found to 
be negatively correlated with the Phe level at diagnosis (r = −0.448; p < 0.0001) but positively correlated with the 
CoQ concentration (r = 0.379; p = 0.003). To further validate this observation, we used the assigned value study 
by classifying 89 PKU patients into 4 groups (2, 5, 8, and 9) according to the type of mutation (Supplementary 
Data Set). Chi-Square test showed a signiicant association between having low plasma CoQ values and belonging 
to group 2 (Chi square = 7.518; p = 0.006). hus, from the 39 cases of group 2, 23 displayed low CoQ values, while 
Figure 2. Box plot representation of: Let panel. Plasma CoQ values (µmol/L) in the 6 subject groups. Middle 
panel. Serum Chol (mmol/L) and Right panel CoQ/Chol values (µmol CoQ/mol Chol) from controls, PKU, 
MPS and IEM patients. Low plasma CoQ concentrations are frequently observed in both PKU and MPS 
patients, while the IEM group show intermediate values. he length of the boxes indicates the interquartile 
space (p25–p75); the horizontal line into the box represents the median (p50), and the circles indicate outlier 
values. *X-axis groups: Group 1: healthy participants. Group 2: phenylketonuric. Group 3: patients with 
mucopolysaccharidoses. Group 4: patients with other inborn errors of metabolism. Group 5: patients with 
neurogenetic diseases. Group 6: individuals with neurological diseases with no genetic diagnosis.
Group (I) Groups (J)
Average 
diference (I-J) 95% conidence interval
CoQ
Controls
PKU 0.164 0.067–0.261 (p < 0.0001)
MPS 0.252 0.127–0.377 (p < 0.0001)
IEM 0.100 −0.013–0.213 (p = 0.139)
CoQ/Chol
Controls
PKU 31.6 11.4–51.8 (p < 0.0001)
MPS 69.4 38.9–99.9 (p < 0.0001)
IEM 24.1 0.4–47.8 (p = 0.043)
MPS
PKU −37.8 −67.4 – −8.4 (P = 0.003)
IEM −45.3 −77.3–13.4 (p = 0.001)
Table 2. ANOVA with Bonferroni correction showed that plasma CoQ values were signiicantly lower in the 
PKU and MPS groups than in controls.  IEM group showed intermediate values that were not signiicantly 
diferent from those of the controls. When we compared the CoQ/Chol ratios in these 3 groups, MPS values 
were signiicantly lower than controls, PKU, and IEM. In turn, IEM and PKU patients showed signiicantly 
lower values than controls.
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16 were normal. In the 34 patients classiied as group 5, 14 showed low CoQ values and 20 were normal. From the 
16 cases belonging to groups 8 and 9, only 1 displayed low CoQ concentrations. Results are represented in Fig. 3.
Regarding the patients with IEM, the percentage of cases with low CoQ values was lower than those of MPS 
and PKU patients (Table 1), and the frequency of low CoQ values was randomly distributed in homocystinurias, 
organic acidurias, and urea cycle defects. We compared (student t test) the plasma CoQ and CoQ/Chol values 
between patients with IEM and carbohydrate-restricted diet (galactosemias and fructosemias) with those taking 
protein-restricted diets (amino acid defects and organic acidemias), and no diferences were observed. Only 
plasma CoQ levels tended to be lower (p = 0.069) in the protein-restricted group, but values normalized when 
they were related to Chol.
he 2 groups of neurological patients did not show any signiicant diferences in plasma CoQ concentrations 
compared with the control group values, and the percentage of cases with low CoQ values was below 8% (Table 1, 
Fig. 2). NGS analysis in selected neurological patients with low plasma CoQ values failed to detect any patho-
genic mutations in genes related to CoQ biosynthesis or associated with secondary CoQ deiciency. However, we 
found two unexpected indings: one patient with an epileptic encephalopathy diagnosed with a channelopathy 
(CACNA1A (NM_023035.2): p.Arg198Gln/c.593 G > A (heterozygous) and another case diagnosed with a Xq28 
duplication syndrome (chrX:154125883–154562336 duplication [436Kb] [heterozygous]). he pathogenicity of 
both mutations was assessed following the recommendations of the American College of Medical Genetics25.
Discussion
To our knowledge, this is the irst work to analyze plasma CoQ and Chol status in a large cohort of pediatric 
patients. We irst conirmed the previously published reference intervals for CoQ and CoQ/Chol values in a 
healthy population of 83 individuals. he concentration of plasma CoQ in healthy subjects has been reported by 
diferent authors in various populations, in general with a good agreement and such values close to those stated in 
the present study26–29. Since CoQ is known to bind to lipoproteins, the amount of CoQ in the plasma can also be 
related to the amount of Chol, and diferences in total CoQ may be normalized to total Chol29. Another important 
observation was that neither plasma CoQ nor CoQ/Chol ratios correlated with the age in the control group (all 
were below 22 years), establishing only one reference interval. hese results are in agreement with other studies29 
and indicate the stability of plasma CoQ status, at least in humans below 22 years.
Other remarkable observation of the present study is that low plasma CoQ values is a common biochemical 
feature in PKU and MPS patients and less frequent in the IEM group (in spite of having restricted diets that 
might lead to CoQ suboptimal status). In these groups, we also analyzed total Chol and calculated CoQ/Chol 
ratio to assess whether these values were concomitantly decreased. PKU is caused by a deiciency in the enzyme 
phenylalanine 4-hydroxylase (EC 1.14.16.1) due to mutations in the PAH gene. Plasma CoQ status is decreased 
in around one-third of the PKU patients compared to an age-matched reference population, as demonstrated 
previously12, as well as in the present study. Several hypotheses may explain this deiciency, although none of them 
have yet been demonstrated in humans, and a combination of diferent factors is the most plausible explanation: 
Firstly, PKU patients avoid foods that are rich sources of CoQ. Secondly, the availability of tyrosine is essential 
for the synthesis of CoQ. Tyrosine may be low in PKU patients, but no association has been reported between the 
lowered plasma tyrosine concentration of patients and their serum CoQ level30. hirdly, other factor associated 
with the decreased plasma CoQ level of PKU patients may be the elevated blood phenylalanine concentrations30, 
since experimentally induced hyperphenylalaninemia in mice has been reported to inhibit the activities of the 
brain and liver enzymes, 3-hydroxy-3-methylglutaryl-CoA reductase, and mevalonate-5-pyrophosphate decar-
boxylase31, which are both essential for CoQ and Chol biosynthesis. Interestingly, plasma CoQ and Chol values 
were decreased in PKU patients, indicating that inhibition of the mevalonate pathway may be the common cause 
of the deicit in CoQ and Chol status. In all likelihood, the factors responsible for the CoQ deiciency in PKU are 
multifactorial, but the demonstration of an association between the predicted PAH residual activity or the type 
of PAH mutations and the CoQ status of the patients supports the hypothesis that the more severe the degree of 
Figure 3. Graphic resprsentation of the assigned value (AV) study results in PKU patients. he black bars 
represent the number of PKU paints displaying low plasma CoQ concentrations in the diferent AV groups. he 
grey bars represent the number of PKU patients with normal plasma CoQ concentration. In AV groups 2 and 
5 (classic PKU), the number of cases displaying low plasma CoQ values is higher than those belonging to AV 
groups 8 and 9 (milder PKU forms).
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hyperphenylalaninemia, the lower the level of plasma CoQ. herefore, the inhibition of the mevalonate pathway 
by high Phe values30,31 would be the most plausible explanation for decreased concentrations of both Chol and 
CoQ.
Regarding the MPS group, only 2 reports demonstrate that a noticeable percentage of patients with a genetic 
diagnosis of MPS present with plasma CoQ deiciency15,32. hose studies did not conduct etiologic investigations 
but raised several hypotheses regarding the presence of low plasdma CoQ values: (1) Impaired liver function 
in MPS, which can cause low plasma CoQ levels; (2) Nutritional problems, although this was unlikely since 
other lipophilic and hydrophilic vitamins were normal in these patients15,32; (3) the most plausible explanation 
for the deicit in plasma CoQ concentrations is related to vitamin B6, which can show low blood levels in MPS 
patients32. he active form of vitamin B6, pyridoxal 5-phosphate, is required for the transamination of tyrosine 
into 4-hydroxyphenylpyruvic acid for CoQ biosynthesis. In this context, a correlation between blood CoQ and 
vitamin B6 status has been demonstrated
33. It is also unknown whether CoQ deiciency is also present in tissues 
and how this may contribute to the pathophysiology of MPS. In the present study, this group displayed the highest 
frequency and most profound low plasma CoQ concentrations, while, in contrast to the PKU group, Chol values 
were not reduced in parallel. Furthermore, the low CoQ values was present in all types of MPS patients except 
for Hurler-Scheie and Maroteaux-Lamy patients. A hypothesis that may account for the CoQ subpotimal status 
in MPS is that heparan sulphate (and probably other mucopolysaccharides), may create adducts with pyridoxal 
5-phosphate, leading to a loss of vitamin B6 and consequently low CoQ concentrations
32. However, this has yet to 
be conirmed or refuted and requires further investigation.
Few reports have stated the association between other IEM under restricted dietary treatments and CoQ 
status. CoQ deiciency has been reported to be associated with propionic and type II glutaric acidurias14,34,35, 
mainly in muscle biopsy. We demonstrate here that none of the groups investigated showed a more consistent 
CoQ deiciency compared with the others. In fact, the IEM group displayed intermediate values between those 
for MPS, PKU, and the controls or the neurological patients. A limitation of the present study is that the IEM 
group is heterogeneous, and one hypothesis that can be drawn is that the contribution of the restricted diets to 
the plasma CoQ concentration would be expected to be limited (lack of diferences between the CoQ values in 
carbohydrate-restricted diet group with that of the normal CoQ availability vs protein-restricted diet group that 
would be at risk of low CoQ intake). hus, the contribution of dietary sources, which has been reported to be 
up to 25% of the total plasma CoQ values3, in the absence of other etiologic mechanisms such as in PKU, would 
explain these intermediate values. Interestingly, the degree of low CoQ values in this group was higher than that 
in the neurological patients, advocating the value of plasma CoQ monitoring in IEM patients, considering that 
these patients will be chronically treated.
Surprisingly, neither the neurogenetic group (including, for example, mitochondrial disorders patients) nor 
the non-diagnosed neurological patients showed reduced plasma CoQ values. Furthermore, the average plasma 
CoQ values in these 2 groups of patients were almost identical to those of the control group. Moreover, the NGS 
assessment of those selected cases with a complex neurological phenotype and CoQ deiciency failed to detect 
pathogenic mutations in the candidate genes, conirming that plasma CoQ status is quite stable, probably tightly 
regulated, and may not be a good biomarker to relect systemic (brain, muscle) CoQ status. hus, plasma CoQ 
would not be a good biomarker to demonstrate genetic diseases associated with CoQ deiciency. In fact, a high 
percentage of mitochondrial disease patients and those having primary genetic disturbances in CoQ biosynthesis 
show a CoQ deicient status in tissues (ibroblast, muscle) but not in plasma36. However, it has been demonstrated 
ater a genome-wide association study that serum CoQ levels identify susceptibility loci linked to neuronal dis-
ease (Alzheimer’s disease, autism, and schizophrenia)37. No patients with these diseases were investigated in the 
present study, and this would explain these diferences.
CoQ values may be inluenced by several genetic and environmental conditions, including changes in dietary 
habits and cholesterol patterns. Since, therefore the variation amongst individuals may be great, single and iso-
lated CoQ determinations in patients are probably no suicient for detecting a real CoQ suboptimal status or for 
indicating CoQ supplementation.
In conclusion, low plasma CoQ values is neither a common inding in most of neuropediatric patients nor a 
good biomarker to predict genetic conditions leading to primary CoQ deiciency. On the contrary, plasma CoQ 
monitoring in selected groups of patients with diferent IEM (especially in PKU and MPS patients, but also in 
organic acidemias and aminoacidopathies under protein-restricted diets) seems advisable to prevent the possi-
bility of a chronic low blood CoQ values in such groups of patients.
Data Availability
he datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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